OTTAWA, CANADA, January 30,2025 – Genomadix (genomadix.com), a global leader in point of need precision medicine diagnostics, announced today that they have received a medical device licence (MDL) ...
A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower healing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results